文献速递妇科肿瘤消化系统肿瘤

细胞减灭术联合腹腔热灌注化疗适应证的系统综述

Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
PubMed 文献 · Eur J Cancer · 2020-01-24

该综述系统检索1985至2019年MEDLINE和EMBASE文献,纳入RCT及控制混杂因素的前瞻性或回顾性对比研究(样本量>30例),评估细胞减灭术(CRS)联合腹腔热灌注化疗(HIPEC)在间皮瘤、阑尾肿瘤、结直肠癌、胃癌、卵巢癌及原发性腹膜癌中的适应证。对于新诊断原发III期上皮性卵巢癌、输卵管癌或原发性腹膜癌,若新辅助化疗后至少疾病稳定且间歇性CRS达到完全或满意减瘤,应考虑CRS联合HIPEC;其余情况证据不足,不推荐在临床试验外使用。

要点

  • 新诊断III期卵巢/输卵管/原发腹膜癌,新辅助化疗后至少稳定且间歇CRS达完全或满意减瘤,可考虑CRS+HIPEC。
  • 初治晚期卵巢癌初次CRS或复发卵巢癌,不推荐临床试验外联合HIPEC。
  • 结直肠癌、胃癌腹膜转移的预防或治疗,不推荐临床试验外CRS+HIPEC。

核心结论

  • 仅新诊断III期上皮性卵巢癌、输卵管癌或原发性腹膜癌患者,在新辅助化疗后至少疾病稳定且间歇性CRS达到完全或满意减瘤时,可考虑CRS联合HIPEC。
  • 其他情况(初治晚期卵巢癌初次CRS、复发卵巢癌、结直肠癌腹膜转移、胃癌腹膜转移、恶性腹膜间皮瘤、阑尾播散性黏液肿瘤)证据不足,不推荐临床试验外使用CRS联合HIPEC。

研究设计与样本

  • 系统综述,检索MEDLINE和EMBASE 1985至2019年发表的文献。
  • 纳入RCT;若无RCT,则纳入控制混杂因素的前瞻性或回顾性对比研究(样本量>30例)。
  • 提取总生存、无进展生存、无复发生存、不良事件和生活质量数据。

关键数值与推荐

  • 新诊断原发III期上皮性卵巢癌、输卵管癌或原发性腹膜癌:新辅助化疗后至少疾病稳定,间歇性CRS达到完全或满意减瘤,应考虑CRS联合HIPEC。
  • 初治晚期卵巢癌初次CRS、复发卵巢癌:证据不足,不推荐临床试验外联合HIPEC。
  • 结直肠癌腹膜转移的预防或治疗:证据不足,不推荐临床试验外CRS联合HIPEC。
  • 胃癌腹膜转移的预防或治疗:证据不足,不推荐临床试验外CRS联合HIPEC。
  • 恶性腹膜间皮瘤或阑尾播散性黏液肿瘤:不推荐作为标准治疗,应转诊至HIPEC专科中心评估研究方案。

临床怎么用

  • 对新诊断III期卵巢/输卵管/原发腹膜癌,新辅助化疗后至少稳定且间歇CRS达完全或满意减瘤者,可考虑CRS联合HIPEC。
  • 初治晚期卵巢癌初次CRS、复发卵巢癌、结直肠癌或胃癌腹膜转移,临床试验外不推荐CRS联合HIPEC。
  • 恶性腹膜间皮瘤或阑尾播散性黏液肿瘤患者应转诊至HIPEC专科中心评估研究方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The purpose of the present review was to describe evidence-based indications for hyperthermic intraperitoneal chemotherapy (HIPEC), with cytoreductive surgery (CRS), in patients with a diagnosis of mesothelioma, appendiceal (including appendiceal mucinous neoplasm), colorectal, gastric, ovarian or primary peritoneal carcinoma. Relevant studies were identified from a systematic MEDLINE and EMBASE search of studies published from 1985 to 2019. Studies were included if they were RCTs. If no RCTs were identified, prospective and retrospecctive comparative studies (where confounders are controlled for studies with greater than 30 patients) were included. Overall survival, progression-free survival, recurrence-free survival, adverse events and quality of life data were extracted. For patients with newly diagnosed, primary stage III epithelial ovarian, fallopian tube or primary peritoneal carcinoma, HIPEC with CRS should be considered for those with at least stable disease following neoadjuvant chemotherapy at the time of interval CRS if complete or optimal cytoreduction is achieved. There is insufficient evidence to recommend the addition of HIPEC when primary CRS is performed for patients with newly diagnosed, primary advanced epithelial ovarian, fallopian tube or primary peritoneal carcinoma or in those with recurrent ovarian cancer outside of a clinical trial. There is insufficient evidence to recommend HIPEC with CRS for the prevention of or for the treatment of peritoneal colorectal carcinomatosis outside of a clinical trial. There is insufficient evidence to recommend HIPEC with CRS for the prevention of or for the treatment of gastric peritoneal carcinomatosis outside of a clinical trial. There is insufficient evidence to recommend HIPEC with CRS in patients with malignant peritoneal mesothelioma or in those with disseminated mucinous neoplasm in the appendix as a standard of care; however, these patients should be referred to HIPEC specialty centres for assessment for treatment as part of an ongoing research protocol.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Auer RC, Sivajohanathan D, Biagi J, et al. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review. Eur J Cancer. 2020. PMID: 31986452. doi:10.1016/j.ejca.2019.10.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。